Salute e Benessere

Patient-Derived Xenograft / PDX Model Market Worth $839 million |…

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Browse in-depth TOC on "Patient-Derived Xenograft / PDX Model Market" 130 - Tables 40 - Figures 180 - Pages Patient-Derived Xenograft / PDX Model Market Scope: Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market...
PR Newswire
18/10/2023

Medical Waste Management Market to Reach US$15.3B by 2033 as Demand Grows to…

NEWARK, Del., Oct. 18, 2023 /PRNewswire/ -- In terms of value, the global net demand for medical waste management systems was estimated to be around US$ 7,592.9 million in 2022. The overall market for medical waste management systems is projected to grow at an annual rate of 6.6% between 2023 and 2033. Following this promising growth rate, the global market value is poised to reach a valuation of around US$ 15,336.9 million by 2033. NEWARK, Del.,Oct. 18, 2023/PRNewswire/ -- In terms of...
PR Newswire
18/10/2023

Nootropic Supplement Market to Register US$ 4,180 Million by 2033 Amid Rising…

As per the recent research report by Future Market Insights (FMI), a research and competitive intelligence provider, the nootropic supplement market is estimated to reach US$ 4,180 million by 2033, surging at 9.0% CAGR by 2033. As per the recent research report by Future Market Insights (FMI), a research and competitive intelligence provider, thenootropic supplement marketis estimated to reach US$ 4,180 million by 2033, surging at9.0%CAGR by 2033. Thesample PDF summary is...
PR Newswire
18/10/2023

Invitation: Sobi's Q3 2023 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards onsobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries,...
PR Newswire
18/10/2023

Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of…

/6i resistant HR+, HER2- metastatic breast cancer. "Dosing the first patient in our Phase 2 clinical trial evaluating the combination of samuraciclib and elacestrant is an important milestone in our goal of improving outcomes for women fighting metastatic breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “Our prior studies have validated the biology for elacestrant with CDK7, and we are eager to evaluate the potential synergistic benefit of this fully…
Nasdaq GlobeNewswire
18/10/2023

KENNAMETAL INTRODUCES NEW TURNING GRADE FEATURING KENGOLD TECHNOLOGY

KCU10B joins the company's KENGold portfolio, which delivers consistency in multi-material cutting, improved wear resistance and enhanced process security—including when used on steels and stainless steels. The innovative coating technology was introduced last year with Kennametal's KCP25C turning grade, setting a new standard for steel turning applications. KCU10B joins the company's KENGold portfolio, which delivers consistency in multi-material cutting, improved wear resistance and…
PR Newswire
18/10/2023

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer…

Cancer is the second leading cause of death worldwide. In 2020, 10 million deaths were attributed to cancer, 70 percent of which occurred in low- and middle-income countries.1 While there are multifaceted reasons for this disparity, a top contributor is the lack of adequate testing, which can lead to prevention, early detection, and advanced treatment. Through the newly announced partnership, SOPHiA GENETICS, MSK, and AstraZeneca will create a decentralized global network for cancer testing…
PR Newswire
18/10/2023

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in…

"We are pleased to see the results from this cardiovascular health outcomes analysis which included long-term follow-up of patients prescribed CONTRAVE®/MYSIMBA®," said Michael Kyle M.D., Currax SVP, Chief Medical Officer. "We plan to share the full study report with both the Food and Drug Administration and the European Medicines Agency in the coming days; and the full HOA study results will be published in a scientific publication in the near future." "We are pleased…
PR Newswire
18/10/2023

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global…

New company will advance Actinium-225 technologies, quickly secure supply, and construct a new production facility in Canada to produce industrial-scale quantities of rare medical isotopeGarching / Munich, Germany and Chalk River, Ontario, Canada, October 18, 2023 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL), which manages and operates the national laboratory at Chalk River, Ontario on...
Nasdaq GlobeNewswire
18/10/2023

Gerresheimer awarded EcoVadis Gold status again

- Status demonstrates consistent implementation of CSR strategy - Status demonstrates consistent implementation of CSR strategy DUESSELDORF, Germany,Oct. 18, 2023/PRNewswire/ --Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma, biotech, and cosmetic industries, has once again been awarded Gold status by the ratings agency EcoVadis. EcoVadis assesses the performance of businesses on environmental, labor and human rights, ethical, and...
PR Newswire
18/10/2023

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of…

Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to anti-CD3 Foralumab Has Been Well-ToleratedAt-Home Dosing Likely to Improve Patient Compliance to Treatment and OutcomesNEW YORK, Oct.18, 2023(GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough...
Nasdaq GlobeNewswire
18/10/2023

Vistin Pharma ASA: Invitation to Q3 2023 conference call

Vistin Pharma ASA will release its third quarter results on Wednesday 25 thof October 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 25th of October at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The third quarter conference call will be available via web and audio through the following access points: Webcast:https://edge...
Nasdaq GlobeNewswire
18/10/2023

Water Street Healthcare Partners Appoints Boris Bernstein as Managing Director…

"I am excited to build on Water Street's strong history of fostering partnerships with entrepreneurs and founders to accelerate their goals for growth. Our mission is to engage our team's industry experience and network of resources in addition to our capital to build businesses into market-leading companies that are contributing to a stronger health care system through their distinctive products, services, and capabilities," emphasized Mr. Bernstein. "I am excited to build on…
PR Newswire
18/10/2023

Loftware Named "Top 100 Healthcare Technology Company" by The Healthcare…

Loftware was selected as a winner for its cloud-based labeling solutions that are designed to meet the unique needs of the healthcare sector. With a focus on accuracy, compliance, and efficiency, Loftware's products enable healthcare professionals, medical device manufacturers, and pharmaceutical companies to streamline their labeling processes while meeting strict regulatory guidelines, improving supply chain visibility, and ensuring patient safety. Loftware was selected as a winner for its...
PR Newswire
18/10/2023

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow…

TZIELD ®Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of MedicineTZIELD met the study's primary endpoint, significantly slowing the decline of C-peptide levels, compared to placeboNumerical trends favoring TZIELD were seen in key secondary endpoints, whilst statistical significance was not achievedPROTECT builds on the...
Nasdaq GlobeNewswire
18/10/2023

Gedeon Richter: an effective treatment for female schizophrenia patients

Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in persistent negative symptoms. Treatment with risperidone is still one of the most used standards when it comes to schizophrenia. Nonetheless according to the Gedeon Richter scientific poster, based on a post-hoc analysis of a randomized, 26-week double blind clinical trial: clinicians observed a significant reduction in global illness severity – that goes beyond negative symptoms – and…
PR Newswire
18/10/2023

SUANFARMA announces a collaboration with Reyoung Pharmaceutical to expand the…

SUANFARMA is committed to health and innovation, which is why it develops and produces accessible raw materials in accordance with the highest regulatory requirements of the EMA or the FDA. Moreover, the company is also devoted to environmentally responsible practices, embracing green chemistry and prioritizing environmental protection. To this end, their robust R&D team works on the development of technologies to achieve maximum efficiency in its processes, to incorporate cutting-edge…
PR Newswire
18/10/2023

Aculys Pharma delivers positive Phase 3 clinical study interim analysis result…

The study demonstrated the drug's effectiveness regarding its primary endpoint, which was the proportion of patients who achieved resolution of clinically relevant seizures within 10 minutes after administration of a single dose and who remained free from seizures or convulsions for 30 minutes after a single dose. Additionally, no adverse events leading to medication discontinuation or serious adverse events causally related to the study drug were observed, and no adverse events related to…
PR Newswire
18/10/2023

Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns

Neonatal sepsis is a leading cause of death for newbornsTesting IL-6 can indicate a neonatal sepsis infection earlier than other biomarkersEarlier diagnosis of neonatal sepsis can lead to improved outcomes and a reduction of long-term complications from sepsisBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries...
Nasdaq GlobeNewswire
18/10/2023

Roche's Alecensa reduces the risk of disease recurrence or death by an…

These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy, 1more effective treatment options are urgently needed to provide the best chance for cure 2 Data are being presented as a late-breaking oral during the ESMO 2023 Presidential...
Nasdaq GlobeNewswire
18/10/2023

Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a…

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0Initial data indicate that DSR 2.0 is safe and well tolerated, restores diuretic response and improves cardiorenal statusBiomarker analysis from RED DESERT and SAHARA studies supports DSR mechanism of action as breaking vicious cycle of cardiorenal syndrome (CRS)Start of randomized cohort of up to...
Nasdaq GlobeNewswire
18/10/2023

BioSenic to draw the final tranches of its present Global Tech Opportunities 15…

INSIDE INFORMATIONMont-Saint-Guibert, Belgium, October 18, 2023, 7.00am CEST –BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024Mont-Saint-Guibert, Belgium, October 18, 2023, 7.00am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has reached a...
Nasdaq GlobeNewswire
18/10/2023

Hyloris announces U.S. FDA Approval of Maxigesic® IV

Maxigesic® IV, a potent non-opioid painkiller, to be marketed in the U.S. under the tradename Combogesic® IVFirst U.S. sales expected in early 2024, triggering a milestone payment of USD 2,1 millionLiège, Belgium – 18 OCTOBER 2023 – 7AM CET – Regulated Information - Inside information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL),a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces Maxigesic® IV has...
Nasdaq GlobeNewswire
18/10/2023

IBA plans total system restoration on its first-ever proton therapy installation

Comprehensive restoration of legacy machine offers the opportunity for sustainable solution Louvain-La-Neuve, Belgium, October 18, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a total system restoration contract with Massachusetts General Hospital (MGH), which was IBA's first-ever proton therapy installation...
Nasdaq GlobeNewswire
18/10/2023
Altri  Comunicati